Drugs / Nyaditum resae
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02897180 | Mar 2017 → Oct 2020 | active tuberculosis | Germans Trias i Pujol Research Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nyaditum resae | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02897180 ↗ |
| Modality | Other / unclassified | “it is considered a food supplement.” PMID 28043488 ↗ Nov 2016 |
| Route | Oral | “which will receive NR (containing 105hkMn) or placebo (orally, every day for 14days).” PMID 28043488 ↗ Nov 2016 |